Artículo de revista
ACE2 and vasoactive peptides: Novel players in cardiovascular/renal remodeling and hypertension
Fecha
2015Registro en:
Therapeutic Advances in Cardiovascular Disease, Volumen 9, Issue 4, 2018, Pages 217-237
17539455
17539447
10.1177/1753944715597623
Autor
Mendoza Torres, Evelyn
Oyarzún, Alejandra
Mondaca Ruff, David
Azocar, Andrés
Chiong Lay, Mario
Castro, Pablo F.
Jalil Milad, Jorge
Lavandero González, Sergio
Ocaranza, María Paz
Institución
Resumen
The renin–angiotensin system (RAS) is a key component of cardiovascular physiology and homeostasis due to its influence on the regulation of electrolyte balance, blood pressure, vascular tone and cardiovascular remodeling. Deregulation of this system contributes significantly to the pathophysiology of cardiovascular and renal diseases. Numerous studies have generated new perspectives about a noncanonical and protective RAS pathway that counteracts the proliferative and hypertensive effects of the classical angiotensin-converting enzyme (ACE)/angiotensin (Ang) II/angiotensin type 1 receptor (AT1R) axis. The key components of this pathway are ACE2 and its products, Ang-(1-7) and Ang-(1-9). These two vasoactive peptides act through the Mas receptor (MasR) and AT2R, respectively. The ACE2/Ang-(1-7)/MasR and ACE2/Ang-(1-9)/AT2R axes have opposite effects to those of the ACE/Ang II/AT1R axis, such as decreased proliferation and cardiovascular remodeling, increased production of nitric oxide